–Treatment with HU6 led to significant reductions in body fat and abdominal visceral fat while preserving skeletal muscle in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) – – HU6, a novel, once-daily, oral therapy in Phase 2 clinical development, is…